Shelby L.Compton

Associate

Irvine + 1.949.553.7565

Connect:

Share

Shelby Compton's practice is focused on M&A, corporate governance, and general corporate and securities matters. She advises public and private companies on domestic and cross-border mergers, acquisitions, and divestitures of all sizes.

Shelby represents clients from a broad range of industries, including biopharmaceuticals, medical devices, pharmaceuticals, technology, energy, telecommunications, and retail. Representative clients include Abbott Laboratories, Astellas Pharma US, the Internet Corporation for Assigned Names and Numbers (ICANN), Sumitomo Corporation, and Western Digital.

Experience

  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day is advising Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Furukawa Electric and Superior Essex global joint venture finalizedJones Day advised Furukawa Electric Co., Ltd. in its finalization of a global joint venture with Superior Essex Inc.
  • Grindr sold to San Vicente Acquisition LLC for $608 millionJones Day advised Grindr in its $608 million sale by Beijing Kunlun Tech Co Ltd of substantially all of the equity interests in Grindr Inc. to San Vicente Acquisition LLC.
  • JTC acquires NES Financial for up to $116 millionJones Day advised JTC PLC in the acquisition of NES Financial, a technology-enabled provider of specialist fund administration and treasury services recognized on the San Francisco Business Times top Bay Area fintech list, for up to $116 million.
  • Advantage Solutions acquires full-service brand, digital, and experiential agencyJones Day advised Advantage Solutions in its acquisition of a full-service brand, digital, and experiential agency.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.
  • Advantage Solutions acquires leading brand manager and marketing agencyJones Day advised Advantage Solutions in its acquisition of a leading brand manager and sales and marketing agency.
  • Misonix acquires Solsys Medical, LLC for $109 millionJones Day advised Misonix, Inc. in its acquisition of Solsys Medical, LLC, a privately held regenerative medical company, in an all-stock transaction valued at approximately $109 million.
  • Western Digital acquires Kazan NetworksJones Day advised Western Digital Corporation (NASDAQ:WDC) in its acquisition of Kazan Networks Corp., a provider of industry leading NVMe™-over-Fabric (NVMe-oF) ASIC and adapter products for next-generation data center architectures.
  • Evidera acquires MedimixJones Day advised Evidera, a business unit of Pharmaceutical Product Development, LLC, in its acquisition of Medimix International, a global technology company providing real-world evidence (RWE) insights and information to the pharmaceutical, diagnostic, and medical device industries.
  • AbbVie acquires MavupharmaJones Day advised AbbVie Inc. in its acquisition of Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon Genes) pathway for the treatment of cancer.
  • Inside Secure acquires Verimatrix for approximately $145 millionJones Day advised Inside Secure in its all cash acquisition of Verimatrix, Inc. for up to approximately $145 million in cash (including a potential earn-out).
    • View All
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.